In: Diagnostic Microbiology and Infectious Disease, 2021, vol. 99, no. 3, p. 115280
The NitroSpeed-Carba NP test was used to rapidly detect and discriminate between the different types of carbapenemases (classes A, B, and D) within 30 minutes among a collection of 202 Pseudomonas sp. strains (mostly Pseudomonas aeruginosa). A total of 99 carbapenemase–(including enzymes exhibiting weak carbapenemase activity such as several Guyana Extended-Spectrum (GES)-ß-lactamases) and...
|
In: The Lancet Infectious Diseases, 2020, vol. 20, no. 5, p. 525–526
|
In: Journal of Global Antimicrobial Resistance, 2020, vol. 23, p. 70–71
|
In: Journal of Infection, 2020, vol. 80, no. 5, p. 578–606
|
In: Journal of Clinical Microbiology, 2020, p. -
A series of clinical NDM-5-producing E. coli isolates obtained from two surveillance networks of carbapenem-producing Enterobacterales from 2018-2019, namely Switzerland (NARA) and Germany (SurvCARE), were analyzed. The 33 NDM-5- producing E. coli isolates were highly resistant to β-lactams including the novel ß- lactam/ß-lactamase inhibitor combinations (ceftazidime/avibactam, ...
|
In: Antimicrobial Agents and Chemotherapy, 2020, vol. 64, no. 3, p. -
Unlike for classes A and B, a standardized amino acid numbering scheme has not been proposed for the class C (AmpC) β-lactamases, which complicates communication in the field. Here, we propose a scheme developed through a collaborative approach that considers both sequence and structure, preserves traditional numbering of catalytically important residues (Ser64, Lys67, Tyr150, and Lys315),...
|
In: Microbial Drug Resistance, 2020, p. -
Objectives: To evaluate the biochemical Rapid ESBL NP® (Liofilchem, Italy) for the rapid detection of extended-spectrum β-lactamases (ESBLs) in Enterobacterales.Methods: A total of 100 clinical gram-negative strains (40 ESBL producers with or without cephalosporinase, 43 carbapenemase producers with or without additional ESBLs, 8 AmpC-type producers, 6 penicillinase producers, and 3 ...
|
In: Antimicrobial Agents and Chemotherapy, 2020, vol. 64, no. 2020-12, p. -
Metallo-β-lactamase (MBL)-producing Escherichia coli isolates resistant to the newly developed β-lactam/β-lactamase inhibitor drug combination aztreonam-avibactam (ATM-AVI) have been reported. Here, we analyzed a series of 118 clinical MBL- producing E. coli isolates of various geographical origins for susceptibility to ATM-AVI. The nature of the PBP3 protein sequence and the occurrence of...
|
In: Journal of Antimicrobial Chemotherapy, 2020, vol. 75, no. 12, p. 3593–3600
Background: Carbapenemase-producing Enterobacterales represent a major therapeutic challenge. MBLs, requiring zinc at their catalytic site, could be inhibited by meso-dimercaptosuccinic acid (DMSA), a heavy metal chelator already widely used for treating lead intoxication.Objectives: To evaluate the activity of carbapenems alone or combined with DMSA against MBL-producing Escherichia coli in...
|
In: Microorganisms, 2020, vol. 8, no. 10, p. 1487
In order to evaluate whether seagulls living on the Lisbon coastline, Portugal, might be colonized and consequently represent potential spreaders of multidrug-resistant bacteria, a total of 88 gull fecal samples were screened for detection of extended- spectrum β-lactamase (ESBL)- or carbapenemase-producing Enterobacteriaceae for methicillin-resistant Staphylococcus aureus (MRSA) and for...
|